Five days into the launch of Medicare's first-ever weight-loss drug coverage program, a significant number of eligible seniors are walking away from pharmacies without their prescriptions, not because they do not qualify, but because of a technical billing disconnect that neither patients nor many pharmacists were fully prepared for.
The Medicare GLP-1 Bridge, launched July 1, 2026, gives eligible Part D enrollees access to Wegovy, Zepbound KwikPen, or Foundayo at a fixed $50 monthly copay for obesity treatment. Up to 3.8 million Medicare beneficiaries may qualify. But in its first days, patients with legitimate eligibility are being turned away — and the reason comes down to how the program is structured.
